Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013743 | 0.83 | DRD2 (0.37) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3008614 | 0.82 | DRD2 (0.36) | KCNH2 | |
| SCHEMBL3018389 | 0.78 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL3030115 | 0.78 | KCNH2 (0.38) | KCNH2PDE4BCYP1A2ALDH1A1 | |
| SCHEMBL3024573 | 0.76 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL3663681 | 0.76 | PDE2A (0.37) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3008126 | 0.76 | MTNR1A (0.34) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3016312 | 0.74 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL3663718 | 0.73 | MTNR1A (0.34) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL19691753 | 0.72 | PRKDC (0.42) | KCNH2RIPK2CYP1A2CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | MTNR1A 4161/4885MTNR1B 3836/4885CA1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.